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Abstract
Two molecularly engineered, live-attenuated West Nile virus (WN) vaccine candidates were highly attenuated and protective in rhesus
monkeys. The vaccine candidates are chimeric viruses (designated WN/DEN4) bearing the membrane precursor and envelope protein genes
of WN on a backbone of dengue 4 virus (DEN4) with or without a deletion of 30 nucleotides (30) in the 3 noncoding region of DEN4.
Viremia in WN/DEN4- infected monkeys was reduced 100-fold compared to that in WN- or DEN4-infected monkeys. WN/DEN4-330
did not cause detectable viremia, indicating that it is even more attenuated for monkeys. These findings indicate that chimerization itself
and the presence of the 30 mutation independently contribute to the attenuation phenotype for nonhuman primates. Despite their high level
of attenuation in monkeys, the chimeras induced a moderate-to-high titer of neutralizing antibodies and prevented viremia in monkeys
challenged with WN. The more attenuated vaccine candidate, WN/DEN4-330, will be evaluated first in our initial clinical studies.
© 2003 Elsevier Inc. All rights reserved.
Introduction
West Nile virus (WN) is a member of the family Flavi-
viridae, and it belongs to the Japanese encephalitis virus
(JE) serocomplex that includes such important human
pathogens as Murray Valley encephalitis, Kunjin, Japanese
encephalitis, and St. Louis encephalitis viruses (Burke and
Monath, 2001; Hayes, 1989). Similar to other members of
this serocomplex, WN is maintained in nature in a mosquito–
bird–mosquito cycle, with humans, horses, and other mam-
mals serving as incidental hosts. WN is widely distributed in
Africa and Europe, where it has usually been associated
with mild illness that includes symptoms of low-grade fe-
ver, headache, rash, myalgia, and polyarthropathy. In 1999,
WN was detected for the first time in the Northeastern part
of the USA, and during the next 3 years, the virus extended
its range to include the southern and western states and
southern Canada (Campbell et al., 2002; CDC Report,
2002). Severe illness has been seen in the USA and is most
common in the elderly, in whom this virus can cause hep-
atitis, meningitis, and encephalitis, leading to paralysis,
coma, and death. Specifically, during the 2002 outbreak of
WN in the USA, there were 3389 WN illnesses reported that
included 201 deaths (CDC Report, 2002). Consequently,
WN illness is considered an emerging disease in the USA
and presents a very significant public health threat. Cur-
rently, a licensed vaccine is not available for the prevention
of WN disease in humans. Mosquito control is the only
strategy available to control WN, but spraying is ineffective
in urban areas, and despite intense efforts, the virus has
spread rapidly within North America and is likely to spread
throughout the hemisphere. Clearly, an effective human
vaccine is urgently needed to protect at-risk populations,
especially since the magnitude of the epidemic continues to
increase (Campbell et al., 2002; CDC Report, 2002).
Advaces in recombinant DNA technology have allowed
us to develop a novel strategy for constructing live-attenu-
ated flavivirus vaccines that we have been pursuing for the
past decade (Pletnev et al., 1992, 2000, 2001; Pletnev and
Men, 1998). Our approach was made possible by the con-
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servation among flaviviruses of genome organization, num-
ber of viral proteins, replicative strategy, gene order and
expression, virion structure, and morphogenesis (Linden-
bach and Rice, 2001). All flaviviruses have a positive-sense,
nonsegmented RNA genome that encodes a single long
polyprotein that is processed by viral or cellular proteases to
yield capsid (C), membrane (M), and envelope glycoprotein
(E) structural proteins followed by nonstructural proteins
NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 (Fig. 1).
These shared properties suggested that viable chimeric vi-
ruses could be produced by replacing the genes for the viral
structural proteins in a full-length infectious cDNA clone of
a flavivirus with the corresponding viral genes of another
distantly related flavivirus. Since the E protein induces
neutralizing protective antibodies, an attenuated chimeric
virus can be used as vaccine against the donor of the E
protein (Burke and Monath, 2001; Pletnev et al., 1992,
2000, 2001; Pletnev and Men, 1998). Vaccine candidates
for tick-borne encephalitis virus (TBE) were created by
replacing the membrane precursor (prM) and E structural
protein genes of the mosquito-borne wild-type dengue virus
type 4 (DEN4) with the corresponding genes from TBE or
the partially attenuated tick-borne Langat virus (LGT), and
the resulting chimeric viruses were attenuated with respect
to neurovirulence and highly attenuated with respect to
neuroinvasiveness in mice (Pletnev et al., 1992, 2000, 2001;
Pletnev and Men, 1998). Each chimera proved to be immu-
nogenic and able to induce resistance in mice against chal-
lenge with TBE or LGT. These findings indicated that a
favorable balance between reduction in virus replication in
vivo (attenuation) and induction of protective immunity
could be achieved through chimerization of flaviviruses.
As a logical extension of this strategy, we previously
constructed a viable WN/DEN4 chimeric virus (Fig. 1) in
which the structural prM and E protein genes of WN were
substituted for the corresponding genes of the distantly
related DEN4 that differed in amino acid sequence by
61.5% for prM and 55.9% for E (Pletnev et al., 2002). The
DEN4 is a desirable backbone for these chimeras for two
reasons: (i) primary infection of humans with DEN4 rarely
results in the severe liver or central nervous system (CNS)
disease seen with other flaviviruses such as yellow fever or
Japanese encephalitis virus (Burke and Monath, 2001), and
(ii) a large menu of mutations, including genetically stable
deletion mutations, are available that can attenuate DEN4
for CNS or hepatic tissue as well as for mosquitoes (Blaney
et al, 2001, 2002; Hanley et al., 2002; Durbin et al., 2001;
Troyer et al., 2001). Previous studies in mice indicated that
WN/DEN4 vaccine candidate was highly attenuated when
tested by either peripheral or direct intracerebral inocula-
tion, whereas its WN parent virus was highly virulent by
both routes (Pletnev et al., 2002). Although the WEN/DEN4
virus was highly attenuated when tested by direct intrace-
rebral inoculation in mice, it retained some residual neuro-
virulence at 104 focus-forming units (FFU), the highest dose
tested. However, it was not clear whether chimerization
itself specified the observed attenuation since the DEN4
virus that constitutes the backbone of the chimera itself is
highly attenuated in mice for neurovirulence and especially
neuroinvasiveness. Use of an animal model in which both
parental viruses replicate efficiently was needed to address
this question, and rhesus monkeys represent such an animal
model (Pletnev et al., 2001; Durbin et al., 2001; Whitehead
et al., 2003).
To generate a further attenuated derivative of WN/DEN4
(Fig. 1), we selected from the menu of DEN4 attenuating
mutations (Blaney et al., 2001, 2002; Hanley et al., 2002;
Durbin et al., 2001; Troyer et al., 2001) a 30-nucleotide dele-
tion mutation in the 3 noncoding region of DEN4 (referred to
here as the 30 mutation). The 30 deletion mutation was
chosen for inclusion in the WN/DEN4 virus because it is a
genetically stable mutation that attenuates dengue virus for
mice, monkeys, mosquitoes, and humans (Blaney et al., 2001,
2002; Hanley et al., 2002; Durbin et al., 2001; Troyer et al.,
2001; Whitehead et al., 2003). Immunization with either the
WN/DEN4 or the WN/DEN4-330 chimeric virus com-
pletely protected mice against lethal challenge with WN (Plet-
nev et al., 2002). The present studies in rhesus monkeys were
Fig. 1. Structure of full-length genome of parental WN or DEN4 and their chimeric viruses. The 5- and 3-termini as well as the shaded regions are from
DEN4; the unshaded regions are from WN. The vertical solid lines represent hydrophobic domains in the polyprotein. 30 indicates the position of a
30-nucleotide deletion in the 3 noncoding region of the DEN4 genome between nucleotides 10478 and 10507 (Durbin et al., 2001). Chimeric viruses were
recovered after transfection of Vero cells with RNA transcripts derived from full-length cDNA as described previously (Pletnev et al., 2002). The prM protein
is cleaved by a host cell protease to yield the mature M protein present in virions.
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initiated to determine whether the addition of the genetically
stable 30 deletion mutation to WN/DEN4 further attenuated
it for a nonhuman primate and to determine whether the WN/
DEN4 and WN/DEN4-330 chimeric viruses exhibited a
satisfactory balance between attenuation and immunogenicity
in a species that is more relevant than mice for the evaluation
of a vaccine that is destined for use in humans. WN/DEN4-
330 virus was found to be more attenuated for rhesus mon-
keys than WN/DEN4, yet it retained sufficient immunogenic-
ity to completely prevent viremia following WN virus
challenge. WN/DEN4-330, therefore, represents a promis-
ing WN vaccine candidate. Furthermore, these data strongly
suggest that both chimerization and the 30 mutation indepen-
dently attenuate this chimeric virus for rhesus monkeys.
Results
Evaluation of WN/DEN4 chimeras in nonhuman primates
Attenuation, immunogenicity, and protective efficacy of
the WN/DEN4 and WN/DEN4-330 chimeric viruses
were studied in a total of 20 rhesus monkeys at the dose of
virus indicated in Table 1. Since peripheral inoculation of
WN virus causes an asymptomatic infection in rhesus mon-
keys, the level of attenuation of chimeric viruses was eval-
uated by comparing the duration and magnitude of viremia
in monkeys infected with a chimeric virus with that of
monkeys infected with the wild-type parental WN virus,
strain NY99, originally isolated from a Chilean flamingo at
the Bronx Zoo in 1999 (Lanciotti et al., 1999) or the DEN4
parental virus, Caribbean strain 814669 (Durbin et al.,
2001). Both wild-type parental viruses were isolated on
multiple days following infection and achieved a virus titer
in serum between 102.2 and 102.9 FFU/ml, indicating that
they were suitable controls for comparison with the chi-
meric vaccine candidates. The level of viremia of WN
wild-type virus was similar at both doses (105 and 106
FFU).
In contrast to wild-type WN, WN/DEN4 induced only a
brief viremia in five of eight monkeys inoculated with 105
or 106 FFU (Table 1). Viremia lasted 1 or 2 days and
attained a peak titer approximately 100-fold lower than that
Table 1
WN/DEN4 chimeric viruses are attenuated and protective in rhesus monkeys
Immunizing virus
(dose, FFU)
Monkey
number
Viremia (log10FFU/ml) on day
postinoculationa
Serum NT antibody
titer on
postimmunization
day 42
Viremia (log10FFU/ml) on
day postchallenge with WN
Serum NT
antibody titer on
postchallenge
day 42
1 2 3 4 5 6 7 WN DEN4 1 2 3 4 5 WN
1. WN/DEN4 (105) 1 — — — — — 0.7 0.7 416 20 — — — — — 981
2 — 0.7 — — — — 0.7 1126 20 — — — — — 2082
3 — — — — — — — 751 20 — — — — — 1210
4 — — — 0.7 — 1.0 — 541 20 — — — — — 1456
GMT: 661 GMT: 1377
2. WN/DEN4 (106) 5 — — — — — — — 675 20 — — — — — 970
6 — 0.7 — — — — — 467 20 — — — — — 1006
7 — — — — — — — 270 20 — — — — — 1039
8 — — — — 0.7 — — 727 20 — — — — — 2334
GMT: 501 GMT: 1240
3. WN/DEN4-3 30
(105)
9 — — — — — — — 109 20 — — — — — 1437
10 — — — — — — — 254 20 — — — — — 462
11 — — — — — — — 170 20 — — — — — 629
12 — — — — — — — 247 20 — — — — — 817
GMT: 186 GMT: 764
4. WN (105) 13 — 2.4 2.2 2.6 2.6 0.7 — 1305 20 — — — — — 2136
14 1.0 2.2 2.6 2.1 2.3 1.0 — 1324 20 — — — — — 2524
GMT: 1318 GMT: 2322
5. WN (106) 15 0.7 2.2 2.7 2.6 2.3 1.0 — 599 20 — — — — — 1424
16 1.9 2.6 2.9 2.6 2.0 — — 842 20 — — — — — 1837
GMT: 708 GMT: 1617
6. DEN4b (106) 17 2.2 2.0 — — — — — 20 754 — 1.7 2.2 2.0 0.7 635
18 2.2 1.9 1.5 1.4 — — — 20 559 — 1.7 2.2 2.0 0.7 600
19 2.2 2.1 0.7 — — — — 20 674 — 0.7 1.4 2.4 0.7 448
20 2.3 2.6 1.5 — — — — 20 565 1.0 1.8 2.0 0.7 — 277
GMT: 20 633 GMT: 467
Note. GMT, geometric mean titer; NT, neutralizing.
a Viremia was not seen in any monkey after day 7 postinoculation. The limit of detectable viremia in serum was 0.7 log10FFU/ml.
b The level of replication of the DEN4 wild-type virus used in this study was comparable to that of the recombinant DEN4 virus that served as backbone
for the WN/DEN4 (Durbin et al., 2001).
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observed in WN or DEN4 virus-infected monkeys. The
level of virus replication of WN/DEN4 remained flat
throughout the entire period of viremia. Notably, each of the
four monkeys inoculated with 105 FFU of the WN/DEN4-3
30 mutant failed to develop a detectable viremia (100.7
FFU/ml), and this degree of additional attenuation from that
of WN/DEN4 was statistically significant (Mann–Whitney
U test; df  7, P  0.05). These observations demonstrate
(i) that WN/DEN4 replicated in a nonhuman primate less
well than either WN or DEN4 parental virus, indicating that
chimerization of WN and DEN4 was responsible for the
attenuation of the chimeric virus observed during infection
of a nonhuman primate and (ii) that the WN/DEN4-330
virus was even more attenuated for monkeys than the un-
modified WN/DEN4 chimera, indicating that the 30 mu-
tation independently attenuates WN/DEN4 for monkeys.
Although the WN/DEN4 chimera and its deletion mutant
were significantly attenuated for rhesus monkeys, these chi-
meric viruses induced a moderate-to-high level of serum
WN neutralizing antibodies (range of 1:270 to 1:1126) in
each immunized animal. The serum neutralizing antibody
titer of monkeys that received WN/DEN-330 was 3.5-
fold lower than that of monkeys infected with a comparable
dose of WN/DEN4 (groups 1 and 3, Table 1; Mann–Whit-
ney U test: df  7, P  0.05), a finding consistent with the
further attenuation caused by the 30 deletion mutation.
Nonetheless, both chimeric viruses induced complete resis-
tance to challenge with 105 FFU of wild-type WN virus
administered subcutaneously on day 42 postimmunization.
WN challenge virus was not detected in the blood of any of
the 12 monkeys immunized with WN/DEN4 or its further
attenuated deletion mutant. The WN challenge virus repli-
cated efficiently only in monkeys previously immunized
with DEN4 virus. Each monkey of this group developed
WN viremia that lasted 4 days and attained a peak titer of
102.0 to 102.4 FFU/ml. This indicated that the observed
resistance induced by the chimeras was not mediated by
their DEN4 components.
The titer of serum neutralizing antibodies against WN
was measured 42 days following challenge with this virus.
Only 1 of 16 monkeys (monkey 9) immunized with the
WN/DEN4 or WN/DEN4-330 chimera or their WN par-
ent developed a significant (four-fold or greater) increase in
serum neutralizing antibody titer after WN challenge. The
total lack of viremia of immunized monkeys following WN
challenge and the failure of 11 of 12 monkeys immunized
with a vaccine candidate to develop a significant antibody
response to WN challenge suggests that WN infection of
immunized monkeys had been largely prevented.
Discussion
Live-attenuated WN chimeric vaccine candidates are
also being generated in which the WN wild-type virus prM
and E protein genes are substituted for those in the yellow
fever virus (YF), strain 17D, a widely used, licensed vaccine
(Arroyo et al., 2001; Monath, 2001). This virus appears to
be attenuated both by chimerization and by the presence of
point mutations in the YF 17D backbone. In the present
study, two molecularly engineered, live-attenuated WN vi-
rus vaccine candidates exhibited different levels of attenu-
ation and were protective in rhesus monkeys and, therefore,
have promise for use as a vaccine to prevent WN disease in
humans. The first vaccine candidate, WN/DEN4, exhibited
greatly reduced viremia during infection of monkeys com-
pared to its WN or DEN4 parental virus, demonstrating that
chimerization itself resulted in attenuation for a nonhuman
primate. This is not surprising since a number of chimeric
flaviviruses have been generated between two wild-type
flaviviruses, and many of these chimeric viruses have
proven to be attenuated in vivo (Pletnev et al., 1992, 1993,
2000, 2001; Bray et al., 1996; Pletnev and Men, 1998).
Importantly, this observation extends previous findings that
demonstrated that the Langat/DEN4 chimera was more at-
tenuated than either parent in rhesus monkeys (Pletnev et
al., 2001). This indicates that chimerization of two mos-
quito-borne flaviviruses as well as chimerization between a
tick-borne and a mosquito-borne flavivirus results in atten-
uation of replication in rhesus monkeys. The decreased
efficiency of interactions of gene products derived from
disparate virus parents is likely the basis for the marked
attenuation exhibited by these chimeric viruses in mice and
monkeys. Importantly, the WN/DEN4 vaccine candidate
achieved a satisfactory balance between attenuation and
immunogenicity in both mice (Pletnev et al., 2002) and
monkeys (present study) in that a high titer of neutralizing
antibodies was induced, and immunized animals were re-
sistant to infection with WN challenge virus. These findings
are consistent with recent studies in mice that showed that B
cells and antibodies play critical roles in prevention of WN
infection (Diamond et al., 2003). Although the genetic basis
for the attenuation phenotype of WN/DEN4 is not com-
pletely understood, it is reasonable to propose that this
phenotype would be stable following replication in vivo
since there is significant sequence divergence between the
WN prM and E and the corresponding DEN4 proteins that
are replaced in the chimeric viruses. This sequence diver-
gence suggests that many nucleotide changes in the WN/
DEN4 virus genome would have to occur following repli-
cation in vivo to restore virulence. If the attenuation
phenotype were unstable, one would expect the level of
replication of the vaccine virus to increase during the period
of replication in vivo (Tolpin et al., 1981), but this was not
observed. Instead, the pattern of viremia observed in each of
the eight monkeys infected with the WN/DEN4 chimeric
virus remained flat throughout the entire period of detect-
able infection as expected for virus with a stable attenuation
phenotype.
Failure to detect viremia in monkeys infected with WN/
DEN4-330 chimera and the induction of a lower level of
serum WN antibodies indicated that this virus was more
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attenuated for a nonhuman primate than WN/DEN4 and that
the 30 mutation independently attenuated the chimera for
monkeys. Thus, WN/DEN4-3 30 chimeric virus is highly
attenuated by two genetically stable attenuating mutations,
namely, chimerization and the 30 mutation. Despite its
high level of attenuation in monkeys, WN/DEN4-330
chimera induced a moderate titer of serum neutralizing
antibodies and completely prevented viremia when mon-
keys were challenged with WN, indicating that it had
achieved a satisfactory balance between attenuation and
immunogenicity. These findings identify the WN/DEN4-
330 chimera as a promising live-attenuated virus vaccine
for humans, and we plan to initiate clinical trials this year
with this candidate.
Materials and methods
Cells and viruses
Simian Vero cells (WHO seed passage 143) were ob-
tained from FDA/WHO via the ATCC. The Vero cells had
been qualified for use in production of candidate human
vaccines and were used to prepare WN and DEN4 parent
viruses and their two chimeric derivatives. The WN wild-
type strain NY99 used in this study was kindly provided by
Dr. R. Lanciotti (CDC, Fort Collins, CO); it was originally
isolated from a Chilean flamingo at the Bronx Zoo (New
York) in 1999 (Lanciotti et al., 1999). Wild-type DEN4
Caribbean strain 814669 prepared in Vero cells was kindly
provided by Dr. S. Whitehead (NIAID). Chimeric WN/
DEN4 and WN/DEN4-330 viruses recovered from full-
length infectious cDNA in Vero cells were the same as
described previously (Pletnev et al., 2002).
Evaluation of parental and chimeric viruses in monkeys
Twenty rhesus monkeys (Macaca mulatta), weighing 3
to 5 kg, were screened for neutralizing antibody before the
study was initiated and were found to be seronegative for
WN and DEN4. Groups of four monkeys were inoculated
subcutaneously (sc) with 105 or 106 FFU of chimeric WN/
DEN4 (clone 18), 105 FFU of WN/DEN4-3 30 deletion
mutant (clone 1), or 106 FFU of wild-type DEN4 strain
814669. Two monkeys were inoculated with 105 FFU of
wild-type WN strain NY99, and two monkeys received 106
FFU of this virus. A 0.5 ml inoculum was administered at
two sites, one on each upper shoulder. Monkeys were bled
daily for 12 days for detection of viremia and on day 42 for
measurement of neutralizing antibody titer. On day 42
postimmunization each of the immunized monkeys was
challenged sc with 105 FFU of wild-type WN. Monkeys
were bled daily for 12 days to test for viremia as well as on
day 84 for measurement of neutralizing antibody. The quan-
tity of virus in monkey serum was determined by direct
titration on Vero cells using WN-specific or DEN4-specific
mouse antibodies to immunostain foci of virus infection as
described previously (Pletnev et al., 2001, 2002). Serum
WN or DEN4 neutralizing antibody titer was determined by
FFU reduction assay for individual serum samples using
wild-type WN or DEN4, respectively (Pletnev et al., 2002).
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